GlassScriptPhysician profile
Laura Miller
NPI 1306207261
$3,900.06
in general payments reported to CMS, 2019-2025
27 companies · $1,081 in 2025
The $1,081 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2021: $122 · 2022: $601 · 2023: $971 · 2024: $961 · 2025: $1,081.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,914 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.90 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $963.28 | 2022-2025 | |
| Viiv Healthcare Company | $799.20 | 2022-2025 | Apretude |
| Pfizer INC. | $262.63 | 2019-2025 | |
| Astellas Pharma US INC | $261.89 | 2023-2024 | Veozah |
| Novo Nordisk INC | $226.15 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Inspire Medical Systems, INC. | $179.42 | 2024 | Inspire |
| Idorsia Pharmaceuticals US INC | $162.72 | 2022-2024 | Quviviq |
| Lilly USA, LLC | $149.62 | 2022-2025 | Zepbound, Mounjaro, Jardiance |
| Exact Sciences Corporation | $146.56 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astrazeneca Pharmaceuticals LP | $97.35 | 2019 | |
| Daiichi Sankyo INC. | $93.67 | 2022-2023 | Injectafer |
| Abbott Laboratories | $79.65 | 2022-2023 | Freestyle Libre 3 |
| Otsuka America Pharmaceutical, INC. | $61.64 | 2023 | Rexulti |
| Abbvie INC. | $58.72 | 2023-2024 | |
| Dexcom, INC. | $57.34 | 2024-2025 | Dexcom G6 Transmitter |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $48.66 | 2022-2025 | Repatha, Repatha, Otezla |
| Sun Pharmaceutical Industries INC. | $47.15 | 2021-2022 | |
| Glaxosmithkline, LLC. | $33.40 | 2021-2024 | Arexvy, Shingrix |
| Hologic Sales and Service, LLC | $32.62 | 2024 | Aptima |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $23.65 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $21.35 | 2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $20.82 | 2021 | |
| Allergan, INC. | $17.00 | 2019 | |
| Sanofi-Aventis U.S. LLC | $16.20 | 2021 | |
| Leo Pharma INC. | $14.80 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $13.14 | 2019 | |
| Janssen Pharmaceuticals, INC | $11.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.